ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Metabolic-Epigenetic Axis of AARS1/IGF2BP3-K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Endometrial cancer (EC) recurrence is strongly associated with enhanced tumor stemness. While lactate-a major tumor-derived metabolite-is known to promote immunosuppression across cancers, its contribution to EC stemness and recurrence remains poorly understood. In this study, we show that elevated protein lactylation in EC correlates with heightened tumor stemness and unfavorable prognosis. Mechanistically, a lactate-enriched microenvironment induces lactylation of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), thereby stabilizing and upregulating the protein. This modification enhances EC stemness by enabling IGF2BP3 to stabilize HMGA2 mRNA via an m6A-dependent pathway, activating downstream stemness-related transcriptional programs. This effect requires lysine 280 (K280) lactylation mediated by alanyl-tRNA synthetase 1 (AARS1), as either AARS1 depletion or IGF2BP3-K280 mutation abolishes lactylation and attenuates stemness. Both genetic and pharmacologic inhibition of IGF2BP3 lactylation markedly suppress tumor growth and stem-like properties in vitro and in vivo. Clinically, IGF2BP3-K280 lactylation correlates with aggressive clinicopathological features and poor survival, outperforming conventional biomarkers in recurrence prediction. Integration of IGF2BP3-K280 lactylation into a clinical nomogram substantially improved recurrence-risk stratification across multi-center cohorts. Collectively, these findings uncover a metabolic-epigenetic mechanism linking lactate metabolism to m6A-mediated stemness regulation, establishing IGF2BP3-K280 lactylation as both a therapeutic vulnerability and a precision biomarker for EC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.